title: Immunogenicity and growth inhibitory efficacy of the prime-boost immunization regime with DNA followed by recombinant vaccinia virus carrying the P29 gene of Babesia gibsoni in dogs.
abstract: In recent studies, heterologous prime-boost approaches, employing plasmid DNA and viral vector pathogen-delivering sequences, have been considered an effective protection strategy for intracellular parasite infections. Here, we evaluated the efficacy of such a strategy against the canine Babesia gibsoni infection. The DNA (pCAGGS-P29) and recombinant vaccinia virus (vvP29) both encoding the P29 of B. gibsoni were used in this study. The dogs were immunized 3 times with priming DNA and boosted once with recombinant virus. The dogs immunized with P29 developed a significant level of IgG2 antibody against P29. The response was strongly boosted by the inoculation of vvP29. The peripheral IFN-gamma responses of the dogs immunized with P29 were significantly higher than those of controls after the parasite inoculation. Moreover, the P29 immunized group showed a significantly low level of parasitemia. In conclusion, this study supports the efficacy of a prime-boost strategy for dogs against canine B. gibsoni infection.
authors.affiliation: National Research Center for Protozoan Diseases, Obihiro University of Agriculture and Veterinary Medicine, Inada-cho, Obihiro, Hokkaido 080-8555, Japan.
authors.forename: Shinya
authors.initials: S
authors.lastname: Fukumoto
authors.forename: Yoh
authors.initials: Y
authors.lastname: Tamaki
authors.forename: Ikuo
authors.initials: I
authors.lastname: Igarashi
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Suzuki
authors.forename: Xuenan
authors.initials: X
authors.lastname: Xuan
mesh_terms: D000818:Animals; D000913:Antibodies, Protozoan / Q000096:biosynthesis; D001403:Babesia / Q000235:genetics / Q000276:immunology*; D001404:Babesiosis / Q000276:immunology / Q000469:parasitology / Q000517:prevention & control*; D015153:Blotting, Western; D004285:Dogs; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005455:Fluorescent Antibody Technique; D015870:Gene Expression; D005822:Genetic Vectors; D007117:Immunization, Secondary; D007074:Immunoglobulin G / Q000096:biosynthesis; D007371:Interferon-gamma / Q000097:blood; D010957:Plasmids; D016052:Protozoan Vaccines / Q000008:administration & dosage / Q000276:immunology; D011897:Random Allocation; D013047:Specific Pathogen-Free Organisms; D014162:Transfection; D014611:Vaccination / Q000379:methods; D019444:Vaccines, DNA / Q000008:administration & dosage / Q000276:immunology; D014616:Vaccinia virus / Q000235:genetics
chemical_list: D000913:Antibodies, Protozoan; D007074:Immunoglobulin G; D016052:Protozoan Vaccines; D019444:Vaccines, DNA; D007371:Interferon-gamma